Body Literacy Without Shame: Reading Sheila de Liz Against the Evidence
An adaptation prompted by the source essay on 身体由我: names, limits and a voice in consultations matter more than memorising a “standard” body.

In this article
The cover is the publisher’s official cover (Beijing Science and Technology Press, 2022, ISBN 9787571418991; image source: the book’s Douban listing, used solely for review and introductory purposes).
Opening: Placing a Book Report in the Evidence Chain

Nordic street scene | The value of body knowledge ultimately lies in a medical relationship in which information is understandable, questions are welcome, and decisions can be shared.
Unverschämt, published in Chinese as My Body Is Mine, is a public introduction to women’s bodies, not a clinical guideline or prescribing manual. This report follows three steps: “the book’s claim—current evidence—reader action.” It first explains the problem the author addresses in each chapter, then checks the strength of evidence against guidelines, systematic reviews, or randomized trials, and finally turns useful actions into a list of questions. This preserves the narrative force of a popular science book without mistaking accessible language for individualized medical conclusions.
Readers need to distinguish three types of information: the author’s opinions, book content that public materials can confirm, and medical evidence added by this report. Numbers, proportions, and words such as “most” or “safe” in a book review can inform real decisions only when the study population, outcome measures, follow-up period, and baseline risk are sufficiently similar. Where these conditions differ, this report explicitly states that direct extrapolation is inappropriate.
| Reading level | Question to answer | This report’s approach |
|---|---|---|
| The book’s narrative | What kind of shame or misunderstanding does the author want to change? | Anchor the discussion in chapter titles and publicly verifiable material, without inventing page numbers or verbatim quotations |
| Medical evidence | What study design supports the conclusion? | Prioritize guidelines, systematic reviews, and randomized controlled trials, and identify limitations |
| Practical action | What can the reader do next? | Translate the discussion into specific questions about appointments, screening, contraception, and shared decisions |
1. Citation Approach and Disclosure: Please Read First

Nordic coastline | A book report needs to read the author’s narrative separately from guidelines, systematic reviews, and randomized trials.
This report did not obtain the full text of My Body Is Mine and therefore cannot check the original page by page. It does not cite any specific page numbers, to avoid fabrication. The report is based on the following publicly verifiable materials:
- The book’s structure: public catalogs from several libraries and platforms, including Guangdong University of Finance and Economics, Zhejiang Gongshang University, and Dedao e-books, consistently confirm 11 chapters, an introduction, and acknowledgments/references.
- Chapter excerpts: quotations or accounts of specific chapters in public media and book reviews, including Tencent News’s quotation from Chapter 7, “The Hollywood of Female Sex Hormones,” reviews by Yeyu Lingfeng and others discussing contraception, painful intercourse, and menopause, and Dedao readers’ chapter reviews.
- The author’s position: Sheila de Liz’s public interviews, including her conversation with Mao Shipian, and public statements in Germany’s popular science community.
- Background clarification: public content from the author’s other menopause book, Die heiße Frau, is used only as background. Material specific to that book—such as its systematic discussion of “bioidentical hormones” and the “golden window,” equol, and details of pelvic floor rehabilitation—is not transplanted into this book. Chapter 7 of the present book offers only an overview in a short section on “hormone replacement therapy and aging healthily.”
Anchoring rule: whenever the discussion below says “the author argues,” the anchor is “Chapter X / subsection title.” This indicates a claim attributable to that chapter and corroborated by public material, rather than a verbatim quotation.
Reference benchmarks (see “References” at the end):
- Chinese Guideline on Menopause Management and Menopausal Hormone Therapy, 2023 Edition, Chinese Journal of Obstetrics and Gynecology
- The North American Menopause Society (NAMS) 2022 Position Statement; NAMS 2023 Nonhormonal Position Statement
- WHO 2021 Guideline for screening and treatment of cervical pre-cancer lesions
- USPSTF / ACS breast cancer screening recommendations; WHO Medical Eligibility Criteria for Contraceptive Use (MEC)
2. The Book’s Position and Central Arguments
| Item | Details |
|---|---|
| Chinese title | My Body Is Mine: Everything About the Fabulous Female Body |
| Original title | Unverschämt: alles über den fabelhaften weiblichen Körper |
| Author | Sheila de Liz, MD, born in 1969 in New Jersey, United States; moved to Germany as a teenager; studied medicine at the University of Mainz; runs her own gynecology practice in Wiesbaden, Germany; more than 30 years of clinical experience |
| Illustrator | Luisa Stömer, winner of the 2018 German Design Award |
| Translator / medical reviewer | Ma Xinhu / Huang Yishu |
| Publication | Beijing Science and Technology Press, January 2022, ISBN 9787571418991, approximately 320 pages |
| Subtitle | Everything About the Fabulous Female Body |
Central arguments throughout the book:
- Dismantle bodily shame: women’s reproductive organs, menstruation, sexuality, and changing hormone levels have long been surrounded by taboo and stigma. Lack of knowledge is itself a source of health risk.
- Empower through informed understanding: knowledge is not intended to frighten women. It helps them move from “passive endurance” to “informed management,” asking doctors questions and participating in decisions.
- Take a life-course perspective: the book covers vulvar anatomy, sexuality, menstruation, sexually transmitted infections, pelvic organs, hormones, contraception, breasts, and urinary/anorectal health in later life—a journey from age 16 to 50 and beyond.
- Challenge the narrative that menopause means life is over: the period of declining hormones is reframed as a transition into “burning years” and remaining “just as cool,” rather than simple decline.
Relationship to current medical consensus: the book’s central themes of destigmatization, improved body literacy, and seeking care while living with one’s body are highly consistent with contemporary patient-centered medical ethics and shared decision-making. On MHT, or menopausal hormone therapy, the author’s encouraging position broadly aligns with the reassessment in current guidelines, but still requires application to individual risk—specifically, the view in NAMS 2022 and China’s 2023 guideline that benefits outweigh risks within the treatment window. Only a few specific assertions, concerning age-related contraindications to combined oral contraceptives after 40 and evolving screening methods, require modest correction using guidelines published after 2023.
3. Chapter-by-Chapter Interpretation and Comparison with the Literature

Nordic harbor | Screening and contraceptive recommendations evolve with technology, age, and risk stratification; familiar advice from older editions cannot stand still.
Chapter 1. The Remarkable Residents of Bikini Bottoms: Vulvar Anatomy
- The author’s argument: extensive metaphors—the clitoris as an “unsung heroine,” and labia ranging “from Barbie to Batwoman”—explain vulvar anatomy systematically, emphasize that structural and individual variation is normal, and challenge anxiety about a “standard vulva.” The chapter also discusses pubic hair styling without medicalizing it.
- Comparison: public education about vulvar anatomy has long been lacking worldwide, and the book fills an important gap. Consistent. One qualification: guidelines on informed consent for current gender-affirming care and external genital cosmetic surgery emphasize depathologization and respect for autonomy. These align with the book’s position that beauty has no single standard and cosmetic changes should be for oneself.
- Limits: the chapter does not explain in detail how to recognize conditions requiring care, such as vulvar lichen sclerosus or vulvar intraepithelial neoplasia (VIN). It is an introduction to body knowledge, not a substitute for education about when a gynecological examination is indicated.
Chapter 2. Sex and That Ecstatic “Oh”
- The author’s argument: vaginal versus clitoral stimulation, the legitimacy of masturbation, and the many causes of painful intercourse, including infection, estrogen deficiency, vulvar lichen sclerosus, and even “psychosomatic difficulty with intercourse—the body saying no.”
- Comparison: highly consistent with modern sexual medicine, such as ISSWSH positions. Reframing painful intercourse from a matter of morality or endurance into a medical signal whose cause needs investigation is one of the book’s most clinically valuable arguments.
- Limits: the author attributes some painful intercourse to a deep reluctance toward one’s partner. This psychosomatic perspective is valid, but the inference must not be reversed: more common causes include atrophic vaginitis, pelvic floor spasm, and endometriosis, among other organic or functional conditions. Clinical care should first exclude physiological causes rather than assume a psychological explanation.
Chapter 3. Menstruation: A Red-Carpet Show with Hidden Currents
- The author’s argument: define normal menstruation and examine heavy bleeding, frequent periods, menstrual pain, absent periods, menstrual product choices, and whether sex during a period is possible.
- Comparison: definitions of abnormal menstrual volume and cycles—for example, heavy menstrual bleeding and the PALM-COEIN classification of abnormal uterine bleeding (AUB)—move in the same direction as current FIGO standards. Consistent.
- Points requiring care: written around 2021, the book does not include more detailed AUB management pathways introduced after 2022, such as tranexamic acid as a first-line nonhormonal treatment for bleeding and the first-line place of the levonorgestrel intrauterine system (LNG-IUS) in heavy menstrual bleeding. The author’s endorsement of sex during menstruation is broadly medically safe, with attention to hygiene and a slightly increased infection risk, and does not conflict with mainstream views. However, the book does not emphasize the relatively higher risk of pelvic inflammatory disease (PID) during menstruation in high-risk groups.
Chapter 4. A Healthy Vagina, a Healthy Body!
- The author’s argument: normal discharge, vulvar itching, odor, vaginal dryness—the “desert flower”—and postpartum pelvic floor changes.
- Comparison: consistent. Connecting vaginal dryness to estrogen levels during breastfeeding and perimenopause, while noting that infection should be excluded, follows the differential diagnosis between genitourinary syndrome of menopause (GSM) and infectious vaginitis.
- Limits: discussing perimenopausal and postmenopausal vaginal atrophy, the book brought the idea that low-dose vaginal estrogen can be used long term into public conversation relatively early. That direction aligns with later guidelines, as discussed under Chapter 7, but the book does not elaborate on formulations or contraindications.
Chapter 5. An Ex-Boyfriend’s “Gift”: Sexually Transmitted Infections
- The author’s argument: use personification and a nonshaming approach to discuss HPV, herpes, chlamydia, gonorrhea, trichomoniasis, and mycoplasma, emphasizing the hidden nature of the “most dangerous pathogens” and the importance of screening.
- Comparison: the range of infections covered aligns with sexually transmitted infection (STI) education. Some points need updating:
- The importance of HPV vaccination is understated: the book mainly presents HPV through a “symphony of warts” and infection risk. Yet WHO had already published its Global Strategy to Accelerate the Elimination of Cervical Cancer in 2020, and HPV vaccination as primary prevention was a global consensus. German vaccination uptake and recommended age frameworks when the book was written differed from today’s. Readers should add the core message of receiving HPV vaccination at an appropriate age.
- Cervical screening methods have changed; see Chapter 6.
Chapter 6. Your Body Is a Fascinating Sanctuary: Vagina, Cervix, Uterus, Fallopian Tubes, Ovaries, Fibroids, Early Pregnancy, and Infertility
- The author’s argument: a panoramic “internal map” of organ functions; uterine fibroids, ovarian cysts, and endometrial polyps are “very common, usually benign, and often need only observation”; distinguish “finding a lesion” from “needing treatment”; and offer a reasoned introduction to early pregnancy and infertility.
- Comparison: reducing anxiety about benign findings is highly consistent with modern evidence-based gynecology—for example, symptom-driven treatment of fibroids, observation of small asymptomatic fibroids, and the frequent spontaneous resolution of physiological ovarian cysts.
- A point requiring guideline correction: cervical cancer screening.
- Based on German/European pathways around 2021, the book emphasizes Pap cytology with or without HPV cotesting. WHO’s 2021 guideline, however, explicitly recommends HPV DNA testing as the preferred primary screening method, every 5–10 years from age 30 for women in the general population, and every 3–5 years from age 25 for women living with HIV.
- Relevant Chinese pathways in 2023 likewise moved toward prioritizing HPV nucleic acid testing. Readers should translate “regular cervical screening” into “prefer HPV testing, or HPV plus cytology, for initial screening and follow-up based on risk,” rather than relying solely on conventional Pap smears.
- Limits: the infertility chapter leans toward reassurance about relaxing one’s mindset, without sufficiently emphasizing the firm constraint of age-related decline in ovarian reserve and the sharp decline in fertility after 35. It should give greater emphasis to the timing of medical evaluation—for example, seeking care after six months of trying without success at age 35 or older.
Chapter 7. The “Hollywood” of Female Sex Hormones: A Key Chapter for This Publication
- Structure: normal physiological cycle → premenstrual syndrome (PMS) → perimenopause or menopause, the “burning years” → hormone replacement therapy and aging healthily → “So what if it’s menopause? I’m still just as cool!”
- The author’s arguments, corroborated by public excerpts:
- A broad account of estrogen’s functions: retaining moisture in skin, supporting collagen, maintaining vaginal moisture and lactobacillus colonization, strengthening bone, protecting cardiovascular health, and more.
- “Postmenopausal women lose 90% of their hormone supply within just a few years,” yet society has done nothing to prepare them.
- A positive presentation of MHT, termed “hormone replacement therapy” in the book, as a medical tool that replaces what is lacking. This position is not radical; it is highly aligned with current mainstream guidelines: for women within the treatment window who have moderate to severe symptoms, MHT has the strongest level of evidence and is the most effective option for symptom relief. It deserves open recommendation, rather than secrecy or embarrassment.
- A quotation attributed to Churchill about not trusting statistics one has not personally falsified reminds readers to assess studies critically. The author is advocating not blind faith but understanding the data and using treatment when appropriate.
- Narratively, the chapter reframes perimenopause as the “burning years” and rejects the stigma of menopause as the end of aging life. This openness and encouragement about hormone therapy is precisely the perspective many women most lack and need.
- Comparison with current guidelines: the core analysis:
| Dimension | Presentation in the book | Current guidelines: China 2023 / NAMS 2022 |
|---|---|---|
| Suitable population | Consider treatment for moderate to severe symptoms | Consistent: MHT is the most effective treatment for vasomotor symptoms (VMS) and GSM. Indications include VMS, GSM, and high osteoporosis risk; China’s 2023 version added premature hypoestrogenic states, such as primary ovarian insufficiency (POI) |
| Timing of initiation | Encourage early assessment rather than enduring symptoms | Consistent and worth encouraging: starting before age 60 or within 10 years of menopause, the “window,” has benefits clearly exceeding risks. NAMS 2022 and China 2023 both explicitly state that benefits outweigh risks. Cardiovascular disease (CVD) risk increases when initiation is delayed beyond the window, so using treatment when appropriate rather than postponing it is the right direction |
| Duration | Leans toward a narrative of possible long-term use | Broadly consistent and more supportive of women: guidelines have removed a rigid five-year limit, replacing it with continued use while symptom benefits remain, contraindications are absent, and reassessment is regular. Many women can therefore use treatment comfortably for years rather than being required to stop at an arbitrary deadline |
| Risk | Notes the need to examine data | Contraindications are explicit: unexplained vaginal bleeding, suspected or known breast cancer, sex-hormone-dependent malignancy, arterial or venous thrombosis within the preceding six months, and severe liver or kidney impairment |
| Route | Overview only | Guidelines favor transdermal treatment, such as patches or gels, for those with a history of thrombosis or migraine, and low-dose local vaginal treatment for GSM to reduce systemic exposure |
Why MHT deserves encouragement: the positive guideline perspective: the author’s friendly presentation is supported by substantial evidence, rather than simply telling readers what they want to hear.
The strongest symptom relief: for vasomotor symptoms such as hot flushes and night sweats, and GSM such as vaginal dryness and recurrent urinary infections, MHT has the highest level of evidence. Sleep, mood, and quality of life often improve substantially within weeks.
Established bone protection: MHT is a reliable means of primary prevention of postmenopausal osteoporotic fractures, with clear benefits when started in perimenopause.
A neutral or even favorable cardiovascular profile within the window: initiation before 60 or within 10 years of menopause does not increase coronary heart disease or stroke risk; some studies suggest lower all-cause mortality.
Other potential benefits: possible reductions in diabetes incidence and colorectal cancer risk, with substantial subjective improvements in mood and cognition.
Put simply, for an appropriate woman at an appropriate time, MHT offers timely relief rather than a reckless gamble. This is the central reason it deserves encouragement.
Key tensions for clinician readers: getting the encouragement right:
- The disagreement over “bioidentical hormones”: in her other book, Die heiße Frau, the author strongly advocates bioidentical hormones. However, NAMS and the Endocrine Society do not recommend custom-compounded bioidentical preparations, which lack randomized safety data on a scale comparable with FDA-approved products. Chapter 7 of the present book provides an overview without exploring the controversy. Readers should understand that guidelines recognize standardized formulations of natural estrogen, 17β-estradiol, plus natural or near-natural progestogen, micronized progesterone—not pharmacy-customized compounds.
- Breast cancer risk needs to be understood in the context of small probabilities: the author’s narrative leans toward the view that hormones were demonized because of flawed study design, referring to misinterpretation of the WHI. Part of this is reasonable: headlines about the WHI were wrongly applied to all women. The fuller picture is more nuanced and reassuring: MHT started in younger women within the window does not increase cardiovascular risk and may confer benefit; its additional breast cancer risk is small, low in absolute terms and lower than several common lifestyle risks including smoking, obesity, and alcohol, and rises slowly, mainly with duration of use. Guideline language calls for individualization, informed choice, the lowest effective dose, and regular assessment. The implication is that most eligible women can use treatment with confidence, rather than treating it as untouchable.
- Nonhormonal options complement rather than oppose hormone treatment: hormones are the book’s main thread, but the NAMS 2023 nonhormonal position statement also confirms effective alternatives. For those who cannot or do not wish to use MHT, evidence-supported options include SSRIs/SNRIs such as paroxetine, escitalopram, and venlafaxine; gabapentin; the NK3 receptor antagonist fezolinetant; cognitive behavioral therapy; and clinical hypnosis. By contrast, soy, isoflavones, and equol have insufficient evidence and are not recommended as treatments. This agrees with this publication’s longer article concluding that food cannot directly replenish estrogen. Encouraging MHT also means respecting the choice of another route.
Chapter 8. Contraception: No Babies on Board
- The author’s argument: hormonal contraception, including combined oral contraceptives (COCs), patches, vaginal rings, implants, and injections; nonhormonal methods such as condoms; and natural contraception. The chapter emphasizes that long-term COC use has “almost no effect on the body,” can reduce ovarian and endometrial cancer risk, and can regulate periods or ease menstrual pain. It also notes that COCs may lower free testosterone and affect desire.
- Comparison:
- The benefits are consistent: COCs can indeed regulate cycles, relieve menstrual pain, and reduce ovarian and endometrial cancer risk, in agreement with the evidence.
- The risk presentation is optimistic and needs correction: modern contraceptive medicine, including WHO MEC and national guidelines, specifies circumstances in which COCs are contraindicated or require caution:
- Age 35 or older and smoking: contraindicated because venous thromboembolism (VTE) risk rises substantially.
- Migraine with aura: contraindicated because of ischemic stroke risk.
- Previous VTE, stroke, CVD, uncontrolled hypertension, or a history of breast cancer: contraindicated or requiring caution.
- The postpartum period and certain autoimmune diseases also require assessment.
- The reassuring phrase “almost no effect” is broadly applicable to younger women without contraindications, but women over 40, this publication’s core readership, need reassessment incorporating age-related contraindications. Smoking after 35 or new migraine with aura moves COCs from a convenient option to one requiring strict medical oversight.
- Natural contraception, or the calendar method, has a high failure rate. The book’s description as a “cool girl’s choice” is somewhat romanticized; modern consensus places it among the least reliable methods and does not recommend it as the principal form of contraception.
Chapter 9. Breasts: Everything About These Two Protrusions
- The author’s argument: breast self-examination—“jelly-like or rice-pudding-like”—benign findings, breast cancer, and the idea that breasts are good whether large or small.
- Comparison:
- Reducing anxiety about benign findings, such as cysts and many proliferative changes, is consistent with current thinking.
- Screening methods need updating: the book emphasizes self-examination, whereas USPSTF recommendations, described in the source as the 2024 draft proposing screening every two years from 40, and ACS place mammography at the center of screening. Breast self-examination (BSE) is no longer routinely recommended for screening, because it may cause false-positive anxiety and unnecessary biopsies. The replacement is breast awareness: knowing one’s usual state and promptly seeking care for changes. Readers should move from “knowing how to self-examine” to “age-appropriate mammography plus awareness of changes.”
Chapter 10. The Other Residents of Bikini Bottoms: Bladder, Urethra, and Anus
- The author’s argument: urinary incontinence, overactive bladder, and perianal health.
- Comparison: consistent. The relationship of stress urinary incontinence to estrogen deficiency and pelvic floor laxity, and the value of pelvic floor rehabilitation and local estrogen, align with urogynecological consensus. This complements Chapter 7’s discussion of vaginal estrogen for GSM.
Chapter 11. Tips for Gynecological Appointments
- The author’s argument: gynecologists practice prevention; care needs time, affection, and gentleness; women should be active and at ease when seeking care.
- Comparison: highly consistent with contemporary patient-centered medical ethics and shared decision-making, bringing the book’s theme of empowerment together. It is especially practical for women over 40: bringing a list and questions to an appointment can itself help reduce missed diagnoses and misjudgments.
4. Critical Themes Across the Book: Tensions with Current Consensus

Nordic fjord | Discussions of hormone therapy need to consider indications, initiation timing, administration route, contraindications, and follow-up together.
- MHT deserves encouragement within the right framework, the area in which reassurance matters most:
The friendly, encouraging presentation of MHT, especially in Chapter 7, is not an exaggeration. Guidelines explicitly state that benefits outweigh risks for symptomatic women within the window who have no contraindications, and treatment deserves open recommendation. Three common-sense boundaries support confident use: ① starting before age 60 / within 10 years of menopause offers the most favorable balance; ② a clinician first excludes contraindications, including breast cancer history, VTE, and unexplained vaginal bleeding; ③ regular follow-up allows adjustment as needed. In other words, both the author and guidelines encourage appropriate use. The task is to find the right doctor and follow the right process, rather than enduring symptoms because one has heard that hormones cause cancer.
The conceptual trap of “bioidentical hormones”: the author’s strong advocacy of bioidentical hormones in her other book is often understood in public discussion as “natural equals safe.” Guidelines distinguish approved, standardized natural hormone preparations from custom-compounded formulations, which are not recommended. These cannot be conflated.
The impression of an easy threshold for contraception poses risks for readers over 40: COCs are safe in younger women, but contraindications become more restrictive with age and factors such as smoking from age 35 or migraine with aura. Because many readers are over 40, guidelines must correct this impression.
Screening technology evolves: primary HPV DNA screening replaces cytology alone, and mammography replaces an emphasis on self-examination. These two updates represent major changes after 2021–2023 and have particularly direct effects on readers’ behavior.
The destigmatizing theme is beyond reproach: removing shame from menstruation, sexuality, the vulva, and menopause fully accords with contemporary patient-centered and depathologizing medical humanities. It is the book’s greatest public contribution.
5. Reading Suggestions for This Publication’s Audience: Women Over 40 and Clinicians
Chapters most worth close reading: Chapter 6, on the cervix, fibroids, and ovaries, alongside WHO’s 2021 screening update; Chapter 7, on hormones and perimenopause, alongside China 2023 and NAMS 2022/2023; Chapter 8, on contraception, alongside WHO MEC age-related contraindications; Chapter 9, on breasts, alongside mammography screening updates; and Chapter 11, on appointments.
Three areas needing guideline supplements:
- Add “treatment window, contraindication assessment, and regular reassessment” to long-term MHT use.
- Add “contraindicated with smoking after 35 or migraine with aura” to the assertion that COCs have almost no effect.
- Add “primary HPV DNA screening and age-appropriate mammography” to cervical screening and breast self-examination.
A quick literature guide for clinician readers: language for practice:
- For perimenopausal concerns, even with regular menstruation, acknowledge that symptoms can precede the final menstrual period by years. Avoid dismissing menopause because periods are still normal. The author also emphasizes this in public interviews, consistent with early recognition in guidelines.
- Discuss MHT confidently and proactively. For eligible women, use the framework of the treatment window, lowest effective dose, transdermal preference with thrombosis or migraine history, and local vaginal treatment for GSM. Explain honestly that initiation within the window has small risks and clear benefits. Breast cancer risk must be explained through absolute risk, treatment duration, regimen, and personal baseline together; saying it is lower than lifestyle risks cannot replace assessment. Also explain regular follow-up and adjustment, turning “Can I use it?” into “How can I use it effectively and confidently?”
- For nonhormonal options, clearly state that SSRIs/SNRIs, gabapentin, fezolinetant, CBT, and hypnosis have supporting evidence. Phytoestrogens—soy, isoflavones, and equol—are not recommended under NAMS 2023.
The practical aim, consistent with this publication’s usual position: knowledge supports the right to informed choices and bringing evidence into shared decisions with a doctor. It does not mean purchasing medication independently or treating a book as a prescription. Any hormone or contraceptive decision should be individualized after the treating clinician assesses indications, contraindications, and situations requiring caution, following the guidelines of the country concerned.
6. Conclusion

Nordic natural landscape | Destigmatization does not remove risk assessment; it brings risk communication back to absolute risk and shared decisions.
My Body Is Mine is an introduction to women’s bodies with substantial public value. Through accessible, taboo-breaking, empowering language, it fills long-concealed knowledge gaps from the vulva to menopause. Its view of women as informed managers of their bodies resonates with contemporary patient-centered medical ethics. For women over 40, its positive presentation of perimenopause, GSM, the pelvic floor, and autonomy in seeking care is especially helpful.
It is not a clinical guideline, however, and two specific areas need guideline supplements: age-related contraindications to COCs after 40, and primary HPV DNA screening/mammography replacing older screening pathways. The most encouraging point is that the book’s openness and encouragement about MHT anticipated the reassessment of evidence. NAMS and China’s 2023 guideline now both say that benefits outweigh risks within the window and that treatment should be used when appropriate, aligning with the author. Readers should use the book as an introduction checked against guidelines: a key that opens the conversation, helping them bring questions to a clinician who shares decisions and treat symptoms that need treatment rather than simply enduring them.
7. References: Comparison Benchmarks

Nordic lakeside | A good book can open a conversation but cannot replace personalized examination, diagnosis, and treatment.
- Menopause Group, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Chinese Guideline on Menopause Management and Menopausal Hormone Therapy, 2023 Edition. Chinese Journal of Obstetrics and Gynecology, 2023.
- The North American Menopause Society. Menopause 2022;29(7):767–794. Position statement on MHT.
- The North American Menopause Society. Menopause 2023. Nonhormonal therapy position statement: SSRIs/SNRIs, gabapentin, fezolinetant, CBT/hypnosis; soy, isoflavones, and equol are not recommended.
- World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, 2021. Primary HPV DNA screening; every 5–10 years from age 30; every 3–5 years from age 25 for women living with HIV.
- U.S. Preventive Services Task Force (USPSTF). Breast cancer screening recommendations, described in the source as the 2024 draft recommending every two years from age 40; breast self-examination is not routinely recommended.
- World Health Organization. Medical Eligibility Criteria for Contraceptive Use (MEC). COC contraindications include smoking at age 35 or older, migraine with aura, and a history of VTE.
- Sheila de Liz, author; Ma Xinhu, translator. My Body Is Mine: Everything About the Fabulous Female Body. Beijing Science and Technology Press, 2022.
- Sheila de Liz. Die heiße Frau, published in Chinese as The Hot You: Everything About the Fabulous Female Menopause. The author’s dedicated menopause book includes systematic discussion of bioidentical hormones and the golden window. It is background only, and its content is not transplanted into the book reviewed here.
- This publication’s earlier article, “Can Estrogen Be Obtained Directly from Everyday Foods?” (2026-10-13): phytoestrogen binding affinity is only 1/100–1/10,000 that of estradiol. NAMS 2023 lists soy, extracts, and equol as not recommended, corroborating the nonhormonal position discussed in this chapter.
(This is a book report comparing public material with the literature. All statements attributed to the author are anchored to chapters and based on publicly available material; no page numbers or verbatim quotations have been invented. Follow the treating clinician and the relevant country’s guidelines for specific care.)
Reader Note
This article is a book report based on public materials, guidelines, and research. It does not provide a diagnosis, prescription, or advice to change or stop medication. Where the book and guidelines differ, the latest guidelines and the treating clinician’s individualized assessment should take precedence.
Read the source material
- NHS: Vaginal dryness
- WHO: Guideline for screening and treatment of cervical pre-cancer lesions
- NICE: Shared decision making NG197
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


